[Ondansetron in carcinoid syndrome].
Buhl
C
C
Fibbe
C
C
Frenzel
H
H
D000284:Administration, Oral; D000368:Aged; D005260:Female; D006801:Humans; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy*; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D017294:Ondansetron
Ondansetron bei Karzinoid-Syndrom.